A2 is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting.
The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised financing of $136 million (The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.
We are currently advancing a pipeline of programs towards the clinic.
A fully integrated discovery, development and manufacturing organization
An experienced management team supported by a renowned Scientific Advisory Board and a Board of Directors with the diverse skills and experience needed to drive success.
Board of Directors
President and Chief Executive Officer, A2 Biotherapeutics
Chief Scientific Officer, A2 Biotherapeutics
President, Innovative Targeting Solutions
Managing Partner, The Column Group
Managing Director, Vida Ventures
Founding Partner, Samsara BioCapital
Partner, Nextech Invest
Chief Operating Officer, Nutcracker Therapeutics